GB9326253D0
(en)
*
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
US5690942A
(en)
*
|
1995-06-02 |
1997-11-25 |
American Home Products Corporation |
Adjuvants for viral vaccines
|
GB9513261D0
(en)
*
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
DK0909323T3
(da)
|
1996-01-04 |
2007-05-21 |
Novartis Vaccines & Diagnostic |
Helicobacter pylori-bakterioferritin
|
GB9616351D0
(en)
*
|
1996-08-02 |
1996-09-11 |
Smithkline Beecham Biolog |
Vaccine composition
|
US20060024301A1
(en)
*
|
1997-02-25 |
2006-02-02 |
Corixa Corporation |
Prostate-specific polypeptides and fusion polypeptides thereof
|
US20030185830A1
(en)
*
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US7517952B1
(en)
*
|
1997-02-25 |
2009-04-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
GB9706957D0
(en)
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
GB9711990D0
(en)
*
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
GB9712347D0
(en)
*
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
CA2654522C
(en)
*
|
1997-08-29 |
2014-01-28 |
Antigenics Inc. |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
|
EP1279401B1
(de)
*
|
1997-09-05 |
2008-01-09 |
GlaxoSmithKline Biologicals S.A. |
Öl-in-Wasser Emulsionen mit Saponinen
|
GB9718901D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US6710226B1
(en)
|
1997-12-02 |
2004-03-23 |
Neuralab Limited |
Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
SI1659178T1
(sl)
|
1998-02-05 |
2010-07-30 |
Glaxosmithkline Biolog Sa |
Postopek za čiščenje ali proizvodnjo MAGE proteina
|
US6451320B1
(en)
*
|
1998-03-09 |
2002-09-17 |
Smithkline Beecham Biologicals S.A. |
Combined hepatitis and herpesvirus antigen compositions
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
GB9806095D0
(en)
*
|
1998-03-20 |
1998-05-20 |
Smithkline Beecham Biolog |
Novel compounds
|
JP4227302B2
(ja)
|
1998-04-07 |
2009-02-18 |
コリクサ コーポレイション |
Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
EP1075276B1
(de)
*
|
1998-05-07 |
2007-10-17 |
Corixa Corporation |
Adjuvanszusammensetzung und methoden zu deren verwendng
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
IL141044A0
(en)
|
1998-08-07 |
2002-02-10 |
Univ Washington |
Innunological herpes simplex virus antigens and methods for use thereof
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
GB9819898D0
(en)
*
|
1998-09-11 |
1998-11-04 |
Smithkline Beecham Plc |
New vaccine and method of use
|
GB9820525D0
(en)
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
GB9822714D0
(en)
|
1998-10-16 |
1998-12-09 |
Smithkline Beecham Sa |
Vaccines
|
EP1588714A2
(de)
|
1998-10-16 |
2005-10-26 |
GlaxoSmithKline Biologicals S.A. |
Adjuvanzsysteme und Impfstoffe
|
WO2000034482A2
(en)
|
1998-12-08 |
2000-06-15 |
Smithkline Beecham Biologicals S.A. |
Novel compounds derived from neisseria meningitidis
|
EP2277892A3
(de)
|
1998-12-08 |
2011-04-27 |
Corixa Corporation |
Verbindungen und Verfahren zur Behandlung und Diagnose von Chlamydia-Infektionen
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
US7198920B1
(en)
|
1999-01-29 |
2007-04-03 |
Corika Corporation |
HER-2/neu fusion proteins
|
US7915238B2
(en)
*
|
1999-02-01 |
2011-03-29 |
Eisai R & D Management Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
AU768574B2
(en)
*
|
1999-02-01 |
2003-12-18 |
Eisai R&D Management Co., Ltd. |
Immunological adjuvant compound
|
US20040006242A1
(en)
|
1999-02-01 |
2004-01-08 |
Hawkins Lynn D. |
Immunomodulatory compounds and method of use thereof
|
US6835721B2
(en)
|
1999-02-01 |
2004-12-28 |
Eisai Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
US6551600B2
(en)
|
1999-02-01 |
2003-04-22 |
Eisai Co., Ltd. |
Immunological adjuvant compounds compositions and methods of use thereof
|
GB2348132B
(en)
*
|
1999-03-02 |
2004-08-04 |
Nedaa Abdul-Ghani Nasif |
Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
|
CZ20013268A3
(cs)
|
1999-03-11 |
2002-02-13 |
Smithkline Beecham Biologicals S. A. |
Nové polypeptidy a polynukleotidy
|
DK1163343T3
(da)
|
1999-03-12 |
2010-04-19 |
Glaxosmithkline Biolog Sa |
Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
|
PL355178A1
(en)
*
|
1999-03-19 |
2004-04-05 |
Smithkline Beecham Biologicals S.A. |
Vaccine
|
GB9909077D0
(en)
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
CA2368014A1
(en)
*
|
1999-03-26 |
2000-10-05 |
Smithkline Beecham Biologicals S.A. |
Casb619 involved in colon cancers
|
KR20020007354A
(ko)
|
1999-04-02 |
2002-01-26 |
길리스 스티브 |
폐암의 치료 및 진단에 유용한 화합물 및 방법
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
CZ303515B6
(cs)
|
1999-04-19 |
2012-11-07 |
Smithkline Beecham Biologicals S. A. |
Adjuvantní prostredek
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
IL146382A0
(en)
*
|
1999-05-13 |
2002-07-25 |
American Cyanamid Co |
Adjuvant combination formulations
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6635261B2
(en)
|
1999-07-13 |
2003-10-21 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9921147D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9923176D0
(en)
|
1999-09-30 |
1999-12-01 |
Smithkline Beecham Biolog |
Novel composition
|
AU1013601A
(en)
|
1999-10-22 |
2001-05-08 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
KR100848973B1
(ko)
|
2000-02-23 |
2008-07-30 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
EP1385541B1
(de)
*
|
2000-04-13 |
2008-06-18 |
Corixa Corporation |
Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
|
ES2303525T3
(es)
|
2000-04-21 |
2008-08-16 |
Corixa Corporation |
Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia.
|
ATE346925T1
(de)
|
2000-05-10 |
2006-12-15 |
Sanofi Pasteur Ltd |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
AU2001268472A1
(en)
*
|
2000-06-16 |
2002-01-02 |
Smith Kline Beecham Corporation |
Icp27-binding polynucleotides
|
AU6867801A
(en)
|
2000-06-20 |
2002-01-02 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
AU2001273149A1
(en)
|
2000-06-28 |
2002-01-08 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AP1695A
(en)
|
2000-06-29 |
2006-12-17 |
Glaxosmithkline Biologicals Sa |
Multivalent vaccine composition.
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
DE60115051T2
(de)
|
2000-07-31 |
2006-08-24 |
Eisai Co., Ltd. |
Immunologische adjuvans verbindungen
|
US7229623B1
(en)
|
2000-08-03 |
2007-06-12 |
Corixa Corporation |
Her-2/neu fusion proteins
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
ES2392943T3
(es)
*
|
2000-10-18 |
2012-12-17 |
Glaxosmithkline Biologicals S.A. |
Vacunas antitumorales
|
GB0025577D0
(en)
*
|
2000-10-18 |
2000-12-06 |
Smithkline Beecham Biolog |
Vaccine
|
EP1201250A1
(de)
*
|
2000-10-25 |
2002-05-02 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Immunogenische Zusammensetzung die hepatische Phaseantigene aus Plasmodium enthält
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
KR20030083682A
(ko)
*
|
2000-11-16 |
2003-10-30 |
유니버시티 오브 메릴랜드, 볼티모어 |
재발성 바이러스 질환의 예방
|
AU3768902A
(en)
|
2000-11-29 |
2002-06-11 |
Xy Inc |
System to separate frozen-thawed spermatozoa into x-chromosome bearing and y-chromosome bearing populations
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
US7306806B2
(en)
|
2001-01-26 |
2007-12-11 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant P. falciparum merozoite protein-142 vaccine
|
WO2002058727A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Walter Reed Army Institute Of Research |
Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
WO2002074336A2
(en)
|
2001-02-23 |
2002-09-26 |
Glaxosmithkline Biologicals S.A. |
Influenza vaccine formulations for intradermal delivery
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
EP1417236A4
(de)
|
2001-07-10 |
2010-03-17 |
Corixa Corp |
Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel
|
EP1420818B1
(de)
*
|
2001-07-26 |
2018-11-21 |
Otago Innovation Limited |
Antigene zusammensetzungen
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0118367D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
DK2224012T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
US7030094B2
(en)
*
|
2002-02-04 |
2006-04-18 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
|
AU2003215316A1
(en)
|
2002-02-20 |
2003-09-09 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
JP4662719B2
(ja)
|
2002-04-19 |
2011-03-30 |
ザ ガバニング カウンシル オブ ザ ユニバーシティ オブ トロント |
アルツハイマー病の処置のための免疫学的方法および組成物
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
EP1532161B1
(de)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vektoren zur expression von hml-2-polypeptiden
|
CA2492598C
(en)
|
2002-07-18 |
2013-12-17 |
University Of Washington |
Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
|
AU2003254792A1
(en)
*
|
2002-08-02 |
2004-02-23 |
Sumitomo Pharmaceuticals Company, Limited |
Bacterial cell wall skeleton component preparaion
|
ES2575014T3
(es)
|
2002-08-02 |
2016-06-23 |
Glaxosmithkline Biologicals S.A. |
Composiciones de vacuna contra Neisseria que comprenden una combinación de antígenos
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US7169548B2
(en)
|
2002-09-13 |
2007-01-30 |
Xy, Inc. |
Sperm cell processing and preservation systems
|
DK2353608T3
(da)
|
2002-10-11 |
2020-02-10 |
Novartis Vaccines And Diagnostics S R L |
Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
|
ES2594758T3
(es)
|
2002-10-23 |
2016-12-22 |
Glaxosmithkline Biologicals S.A. |
Procedimientos de vacunación contra la malaria
|
WO2004046177A2
(en)
|
2002-11-15 |
2004-06-03 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US7858098B2
(en)
|
2002-12-20 |
2010-12-28 |
Glaxosmithkline Biologicals, S.A. |
Vaccine
|
WO2004061423A2
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
EP2289546A3
(de)
|
2003-01-30 |
2011-03-30 |
Novartis Vaccines and Diagnostics S.r.l. |
Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
|
DK2308417T3
(da)
|
2003-03-28 |
2016-07-04 |
Inguran Llc |
Apparat og fremgangsmåder til tilvejebringelse af sorterede partikler
|
WO2004087204A2
(en)
|
2003-04-04 |
2004-10-14 |
Pfizer Products Inc. |
Microfluidized oil-in-water emulsions and vaccine compositions
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7731967B2
(en)
*
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
CA2528007C
(en)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
EP1667712B1
(de)
|
2003-10-02 |
2010-07-21 |
GlaxoSmithKline Biologicals S.A. |
B. pertussis antigene und ihre verwendung bei der vakzinierung
|
PT1670506E
(pt)
|
2003-10-02 |
2013-01-28 |
Novartis Ag |
Vacinas líquidas para serogrupos meningocócicos múltiplos
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP2561884B1
(de)
|
2004-02-05 |
2017-01-04 |
The Ohio State University Research Foundation |
Chimäre VEGF-Peptide
|
EP1722815A1
(de)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza-virus-vakzine
|
CA2564180A1
(en)
*
|
2004-04-22 |
2005-11-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
Pharmaceutical preparation containing bacterial cell wall skeleton component
|
EP1740217B1
(de)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Meningokokken-konjugat-impfung
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
US20080199493A1
(en)
|
2004-05-25 |
2008-08-21 |
Picker Louis J |
Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
|
DE602005025342D1
(de)
|
2004-05-28 |
2011-01-27 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
US7758866B2
(en)
|
2004-06-16 |
2010-07-20 |
Glaxosmithkline Biologicals, S.A. |
Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
|
US8085126B2
(en)
*
|
2004-07-27 |
2011-12-27 |
Honeywell International Inc. |
Identification with RFID asset locator for entry authorization
|
JP2008508320A
(ja)
|
2004-07-29 |
2008-03-21 |
カイロン コーポレイション |
Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2181714A3
(de)
|
2004-09-22 |
2010-06-23 |
GlaxoSmithKline Biologicals S.A. |
Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
|
US8846051B2
(en)
|
2004-10-08 |
2014-09-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by deoptimization of synonymous codons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
JP4993750B2
(ja)
|
2005-01-27 |
2012-08-08 |
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド |
髄膜炎菌に起因する疾患に対する広域防御のための、gna1870を基にした小胞ワクチン
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
EP1858920B1
(de)
|
2005-02-18 |
2016-02-03 |
GlaxoSmithKline Biologicals SA |
Proteine und nukleinsäuren von meningitis-/sepsis-assoziierten escherichia coli
|
AU2006216844B2
(en)
|
2005-02-18 |
2012-11-08 |
Novartis Vaccines And Diagnostics S.R.L. |
Immunogens from uropathogenic escherichia coli
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0506001D0
(en)
*
|
2005-03-23 |
2005-04-27 |
Glaxosmithkline Biolog Sa |
Novel use
|
US20090081253A1
(en)
*
|
2005-03-23 |
2009-03-26 |
Glaxosmithkline Biologicals S.A. |
Composition
|
EP2392347A3
(de)
|
2005-03-31 |
2012-01-18 |
GlaxoSmithKline Biologicals S.A. |
Impfstoffe gegen Chlamydieninfektion
|
US20070292418A1
(en)
*
|
2005-04-26 |
2007-12-20 |
Eisai Co., Ltd. |
Compositions and methods for immunotherapy
|
AU2006241206B2
(en)
*
|
2005-04-26 |
2011-06-09 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
JP5164830B2
(ja)
|
2005-04-29 |
2013-03-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
結核菌感染の予防または治療のための新規方法
|
AU2006261342B2
(en)
|
2005-06-15 |
2012-02-02 |
The Ohio State University Research Foundation |
Her-2 peptides
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
BRPI0613168A2
(pt)
|
2005-07-01 |
2010-12-21 |
Forsyth Dental In Ry For Children Fa |
molécula de polipeptìdeo isolada; molécula de ácido nucléico isolada; vetor ou plasmìdeo; célula hospedeira; anticorpo; proteìna de fusão; método para estimular uma resposta imunogênica especìfica à tb em um indivìduo ou para prevenir ou reduzir a gravidade de doença causada pela tb; método para monitorar o tratamento da doença causada pela tb em um indivìduo; método de diagnóstico de doença causada pela tb em um indivìduo; método de distinção entre a doença causada pela tb e a imunidade à doença causada pela tb em um indivìduo; método para detecção da infecção por m. tuberculosis em uma amostra biológica; composição; kit para diagnóstico da presença ou da ausência de infecção por m. tuberculosis em uma pessoa; e composição farmacêutica
|
JP2009509675A
(ja)
*
|
2005-09-30 |
2009-03-12 |
Tti・エルビュー株式会社 |
新規薬学的ビヒクルを用いる経皮薬剤送達システム、装置、及び方法
|
GB0519871D0
(en)
|
2005-09-30 |
2005-11-09 |
Secr Defence |
Immunogenic agents
|
JP2009509634A
(ja)
*
|
2005-09-30 |
2009-03-12 |
Tti・エルビュー株式会社 |
官能基化マイクロニードル経皮薬剤送達システム、装置及び方法
|
KR20080066712A
(ko)
*
|
2005-09-30 |
2008-07-16 |
티티아이 엘뷰 가부시키가이샤 |
관능화된 미세바늘 경피 약물 전달 시스템, 장치 및 방법
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
JP2009514839A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
EA014028B1
(ru)
*
|
2005-11-04 |
2010-08-30 |
Новартис Вэксинс Энд Диагностикс Срл |
Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа
|
JP2009514838A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP1948232A4
(de)
*
|
2005-11-18 |
2010-09-22 |
Univ Ohio State Res Found |
Virale genprodukte und verfahren zur schutzimpfung vor viruserkrankungen
|
WO2007061964A1
(en)
*
|
2005-11-18 |
2007-05-31 |
3M Innovative Properties Company |
Methods for coating microneedles
|
JP5215865B2
(ja)
|
2005-11-22 |
2013-06-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
ノロウイルス抗原およびサポウイルス抗原
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
*
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
TW201350129A
(zh)
|
2005-12-22 |
2013-12-16 |
Glaxosmithkline Biolog Sa |
包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20080033398A1
(en)
*
|
2005-12-29 |
2008-02-07 |
Transcutaneous Technologies Inc. |
Device and method for enhancing immune response by electrical stimulation
|
MX2008009280A
(es)
|
2006-01-17 |
2008-12-12 |
Arne Forsgren |
Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
|
KR20110110853A
(ko)
|
2006-01-27 |
2011-10-07 |
노파르티스 파르마 아게 |
적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
|
EP2357184B1
(de)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazochinoxalinverbindungen als Immunmodulatoren
|
US8063063B2
(en)
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
CA2646349A1
(en)
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Storage of influenza vaccines without refrigeration
|
CA2647441C
(en)
|
2006-03-30 |
2021-02-23 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition comprising staphylococcus aureus saccharides
|
CA2647939A1
(en)
|
2006-03-30 |
2007-11-08 |
Embrex, Inc. |
Methods and compositions for vaccination of poultry
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
EP2390360A1
(de)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals S.A. |
Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IDO1
|
WO2008020335A2
(en)
|
2006-06-09 |
2008-02-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
CA2654709A1
(en)
|
2006-06-12 |
2007-12-21 |
Nathalie Devos |
Neisseria meningitidis lipooligosaccharide vaccine
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
US8128921B2
(en)
*
|
2006-07-11 |
2012-03-06 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
KR101696727B1
(ko)
|
2006-07-17 |
2017-01-16 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
인플루엔자 백신
|
DK2422810T3
(da)
|
2006-07-17 |
2014-11-24 |
Glaxosmithkline Biolog Sa |
Influenzavaccine
|
US9364525B2
(en)
|
2006-07-18 |
2016-06-14 |
Glaxosmithkline Biologicals Sa |
Vaccines for malaria
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
GB2453475B
(en)
|
2006-07-25 |
2011-01-19 |
Secr Defence |
Live vaccine strain
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
DK2066341T3
(en)
*
|
2006-09-01 |
2015-10-19 |
Csl Ltd |
PROCEDURE FOR INITIATING OR INDUCING AN IMMUNE RESPONSE
|
PT2097102E
(pt)
|
2006-09-07 |
2012-08-03 |
Glaxosmithkline Biolog Sa |
Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
|
AU2007297178B2
(en)
|
2006-09-11 |
2014-07-24 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
PT2068918E
(pt)
|
2006-09-26 |
2012-08-06 |
Infectious Disease Res Inst |
Composição para vacina contendo adjuvante sintético
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2433648A3
(de)
|
2006-10-12 |
2012-04-04 |
GlaxoSmithKline Biologicals S.A. |
Impfstoff mit einem Öl-in-wasser-emulsionshilfsstoff
|
ES2397714T3
(es)
*
|
2006-10-12 |
2013-03-08 |
Glaxosmithkline Biologicals S.A. |
Vacuna que comprende un adyuvante de emulsión de aceite en agua
|
GB0622282D0
(en)
|
2006-11-08 |
2006-12-20 |
Novartis Ag |
Quality control methods
|
AU2007330494B2
(en)
|
2006-12-06 |
2014-03-13 |
Seqirus UK Limited |
Vaccines including antigen from four strains of influenza virus
|
CA2896131C
(en)
|
2007-03-02 |
2020-04-07 |
Glaxosmithkline Biologicals S.A. |
Novel method and compositions
|
US8486414B2
(en)
|
2007-04-04 |
2013-07-16 |
Infectious Disease Research Institute |
Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
|
AR066405A1
(es)
|
2007-04-20 |
2009-08-19 |
Glaxosmithkline Biolog Sa |
Vacuna
|
EA200901340A1
(ru)
|
2007-05-02 |
2010-04-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцина
|
GB0711858D0
(en)
*
|
2007-06-19 |
2007-07-25 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
NZ582595A
(en)
|
2007-06-27 |
2012-07-27 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EA017887B1
(ru)
|
2007-08-02 |
2013-03-29 |
Байондвакс Фармасьютикалз Лтд. |
Полимерные мультиэпитопные вакцины против гриппа
|
CA2695421A1
(en)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
UY31285A1
(es)
|
2007-08-13 |
2009-03-31 |
|
Vacunas
|
CA2699513C
(en)
|
2007-09-12 |
2018-03-13 |
Novartis Ag |
Gas57 mutant antigens and gas57 antibodies
|
BRPI0817008A2
(pt)
|
2007-09-17 |
2017-05-16 |
Glaxosmithkline Biologicals Sa |
oligonucleotídeo, inciador ou sonda, par de iniciadores, kit, métodos para detectar a presença e/ou a quantidade do gene mage-a3 não metilado e metilado em uma amostra a contendo dna, para diagnosticar câncer ou predisposição ao câncer ou predisposição ao câncer, para identificar e/ou selecionar um paciente adequado para tratamento com um imunoterapêutico de mage-a3, para predizer a probabilidade de tratamento bem sucedido do câncer, para selecionar um regime de tratamento adequado para câncer, para tratar câncer em um paciente, para tratar um paciente suscetível á recorrência de um tumor expressando mage-a3, e, uso de uma composição
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
EP2227250A4
(de)
|
2007-12-03 |
2011-07-06 |
Harvard College |
Chlamydia-antigene
|
WO2009071633A1
(en)
*
|
2007-12-06 |
2009-06-11 |
Glaxosmithkline Biologicals S.A. |
Influenza composition
|
WO2009076158A1
(en)
*
|
2007-12-07 |
2009-06-18 |
Novartis Ag |
Compositions for inducing immune responses
|
US10040825B2
(en)
|
2007-12-19 |
2018-08-07 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
PL2235046T3
(pl)
|
2007-12-21 |
2012-12-31 |
Novartis Ag |
Zmutowane formy streptolizyny O
|
US8092813B1
(en)
|
2007-12-28 |
2012-01-10 |
Novartis Ag |
Polychlorinated biphenyls and squalene-containing adjuvants
|
EP3263591B1
(de)
|
2008-02-21 |
2019-03-27 |
GlaxoSmithKline Biologicals S.A. |
Meningokokken-fhbp-polypeptide
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
WO2009126816A1
(en)
*
|
2008-04-09 |
2009-10-15 |
Ventria Bioscience |
Production of ospa for lyme disease control
|
CN102099052A
(zh)
*
|
2008-04-16 |
2011-06-15 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗
|
ES2651924T3
(es)
|
2008-04-18 |
2018-01-30 |
The General Hospital Corporation |
Inmunoterapias que emplean vacunas autoensamblantes
|
AU2009248810B2
(en)
|
2008-05-23 |
2013-12-05 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
KR101507822B1
(ko)
|
2008-06-04 |
2015-04-24 |
잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 |
불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
|
KR101701198B1
(ko)
|
2008-06-19 |
2017-02-01 |
배리에이션 바이오테크놀로지스 아이엔씨. |
인플루엔자를 치료하기 위한 조성물 및 방법
|
US20110150926A1
(en)
*
|
2008-08-01 |
2011-06-23 |
Mohammed Alsharifi |
Influenza vaccines
|
ATE513920T1
(de)
|
2008-08-28 |
2011-07-15 |
Novartis Ag |
Herstellung von squalen aus hyperproduzierenden hefen
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
CA2738245A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
US9974844B2
(en)
|
2008-11-17 |
2018-05-22 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
GB0822001D0
(en)
*
|
2008-12-02 |
2009-01-07 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2010064243A1
(en)
|
2008-12-03 |
2010-06-10 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
PE20142330A1
(es)
|
2008-12-09 |
2015-01-14 |
Pfizer Vaccines Llc |
Vacuna de peptido ch3 de ige
|
CN102257135B
(zh)
|
2008-12-16 |
2017-06-09 |
纳米医疗公司 |
流感疫苗的生产
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
GB0900455D0
(en)
|
2009-01-13 |
2009-02-11 |
Secr Defence |
Vaccine
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
ES2608841T3
(es)
|
2009-02-10 |
2017-04-17 |
Seqirus UK Limited |
Vacunas contra la gripe con cantidades reducidas de escualeno
|
SG2014014385A
(en)
*
|
2009-02-17 |
2014-04-28 |
Glaxosmithkline Biolog Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
EA021100B1
(ru)
|
2009-03-17 |
2015-04-30 |
МДхХЭЛС СА |
Усовершенствованное определение экспрессии генов
|
WO2010119343A2
(en)
|
2009-04-14 |
2010-10-21 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
CA2757620C
(en)
|
2009-04-30 |
2016-04-26 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
KR20120014054A
(ko)
|
2009-05-27 |
2012-02-15 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Casb7439 작제물
|
HUE031051T2
(en)
|
2009-06-05 |
2017-06-28 |
Infectious Disease Res Inst |
Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
|
WO2010146414A1
(en)
|
2009-06-15 |
2010-12-23 |
National University Of Singapore |
Influenza vaccine, composition, and methods of use
|
EP2442827B1
(de)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsionsimpfstoffe
|
AU2010270722B2
(en)
|
2009-07-06 |
2015-06-04 |
Variation Biotechnologies, Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
CA2803282C
(en)
|
2009-07-06 |
2018-05-01 |
David E. Anderson |
Methods for preparing vesicles and formulations produced therefrom
|
EP2451833B1
(de)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Konservierte escherichia-coli-immunogene
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
MX2012000734A
(es)
|
2009-07-16 |
2012-01-27 |
Novartis Ag |
Inmunogenos destoxificados de escherichia coli.
|
JP5646620B2
(ja)
|
2009-07-17 |
2014-12-24 |
インダストリー アカデミック コーポレーション ファウンデーション, ハルリム ユニバーシティー |
リポソームに被包されたオリゴヌクレオチド及びエピトープを含む免疫増強用組成物
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
JP2013502918A
(ja)
|
2009-08-27 |
2013-01-31 |
ノバルティス アーゲー |
髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
|
JP2013503623A
(ja)
|
2009-09-03 |
2013-02-04 |
ファイザー バクシーンズ エルエルシー |
Pcsk9ワクチン
|
RU2555342C2
(ru)
*
|
2009-09-10 |
2015-07-10 |
Мериал Лимитед |
Новые вакцинные составы, включающие сапонинсодержащие адъюванты
|
CN102695523A
(zh)
|
2009-09-10 |
2012-09-26 |
诺华有限公司 |
针对呼吸道疾病的组合疫苗
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
US20130022639A1
(en)
|
2009-09-30 |
2013-01-24 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
US8974799B2
(en)
|
2009-09-30 |
2015-03-10 |
Novartis Ag |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
NZ599666A
(en)
|
2009-10-09 |
2014-11-28 |
Cbio Ltd |
Chaperonin 10 variants
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
MX2012004850A
(es)
|
2009-10-27 |
2012-05-22 |
Novartis Ag |
Polipeptidos fhbp meningococicos modificados.
|
GB0918830D0
(en)
|
2009-10-27 |
2009-12-09 |
Glaxosmithkline Biolog Niederl |
Process
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
CN107412754A
(zh)
|
2009-12-22 |
2017-12-01 |
塞尔德克斯医疗公司 |
疫苗组合物
|
US20110159031A1
(en)
|
2009-12-22 |
2011-06-30 |
Baxter International Inc. |
Vaccine to Influenza A Virus
|
ES2707778T3
(es)
|
2009-12-30 |
2019-04-05 |
Glaxosmithkline Biologicals Sa |
Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
|
EP2353609A1
(de)
|
2010-02-04 |
2011-08-10 |
Sanofi Pasteur |
Immunisierungszusammensetzungen und -verfahren
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
WO2011110635A1
(en)
|
2010-03-10 |
2011-09-15 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
WO2011112871A1
(en)
|
2010-03-11 |
2011-09-15 |
Immune Design Corp. |
Vaccines for pandemic influenza
|
WO2011117408A1
(en)
|
2010-03-26 |
2011-09-29 |
Glaxosmithkline Biologicals S.A. |
Hiv vaccine
|
ES2910199T3
(es)
|
2010-03-30 |
2022-05-11 |
Childrens Hospital & Res Center At Oakland |
Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(de)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
|
GB201006324D0
(en)
|
2010-04-15 |
2010-06-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
CN102933229A
(zh)
|
2010-06-04 |
2013-02-13 |
惠氏有限责任公司 |
疫苗制剂
|
CA2798837A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
EP2942061A3
(de)
|
2010-06-07 |
2016-01-13 |
Pfizer Vaccines LLC |
Ige-ch3-peptidimpfstoff
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
CN103154242B
(zh)
|
2010-07-06 |
2015-09-30 |
诺华股份有限公司 |
诺如病毒衍生的免疫原性组合物和方法
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
CA2840079C
(en)
|
2010-07-06 |
2018-07-03 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130259948A1
(en)
|
2010-09-21 |
2013-10-03 |
National Institute Of Immunology |
Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
|
SG188624A1
(en)
|
2010-09-27 |
2013-04-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
BR112013011420A2
(pt)
|
2010-11-08 |
2016-08-02 |
Infectious Disease Res Inst |
vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
AU2011335551B2
(en)
|
2010-12-02 |
2016-10-06 |
Bionor Immuno As |
Peptide scaffold design
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
MX346475B
(es)
|
2011-01-06 |
2017-03-22 |
Bionor Immuno As |
Peptidos inmunogenicos monomericos y multimericos.
|
BR112013017939B1
(pt)
|
2011-01-13 |
2022-11-16 |
Variation Biotechnologies Inc |
Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
|
CA2862871C
(en)
|
2011-01-13 |
2020-09-22 |
Variation Biotechnologies Inc. |
Methods for preparing vesicles and formulations produced therefrom
|
EP4159232A1
(de)
|
2011-01-26 |
2023-04-05 |
GlaxoSmithKline Biologicals S.A. |
Rsv-immunisierungstherapie
|
CA2825403C
(en)
|
2011-01-27 |
2023-02-21 |
Gamma Vaccines Pty Limited |
Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
|
CA2828068C
(en)
|
2011-02-22 |
2019-03-19 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
EP2691422B1
(de)
|
2011-03-29 |
2019-02-06 |
UAB Research Foundation |
Verfahren und zusammensetzungen für ein cytomegalovirus-il-10 protein
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
US20120288515A1
(en)
|
2011-04-27 |
2012-11-15 |
Immune Design Corp. |
Synthetic long peptide (slp)-based vaccines
|
HUE034673T2
(en)
|
2011-05-13 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Pre-fusion Rsv F antigens
|
CA2834834A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
EP2717909B1
(de)
|
2011-06-04 |
2017-12-06 |
Rochester General Hospital Research Institute |
Zusammensetzungen und verfahren in zusammenhang mit p6 von haemophilus influenzae
|
CN103608030A
(zh)
|
2011-06-21 |
2014-02-26 |
昂科发克特公司 |
用于治疗和诊断癌症的组合物和方法
|
EP2726097A4
(de)
|
2011-07-01 |
2015-03-11 |
Univ California |
Herpes-virus-impfstoff und verwendungsverfahren
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US10206996B2
(en)
|
2011-08-22 |
2019-02-19 |
Nanobio Corporation |
Herpes simplex virus nanoemulsion vaccine
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
JP6460792B2
(ja)
|
2011-09-09 |
2019-01-30 |
ナノバイオ コーポレーション |
ナノエマルション呼吸器合胞体ウイルス(rsv)サブユニットワクチン
|
EP2755994A2
(de)
|
2011-09-14 |
2014-07-23 |
Novartis AG |
Impfstoffkombination gegen escherichia coli
|
TR201909110T4
(tr)
|
2011-09-14 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
|
SI2758432T1
(sl)
|
2011-09-16 |
2019-07-31 |
Ucb Biopharma Sprl |
Nevtralizirajoča protitelesa proti glavnim eksotoksinom TCDA in TCDB iz clostridium difficile
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
ES2812564T3
(es)
|
2011-11-23 |
2021-03-17 |
Bioven 3 Ltd |
Proteínas recombinantes y sus usos terapéuticos
|
EP2788477A2
(de)
|
2011-12-07 |
2014-10-15 |
Institut Pasteur |
Identifizierung des porcinen parecho-like virus und anwendungen
|
MX2014006630A
(es)
|
2011-12-08 |
2014-07-09 |
Novartis Ag |
Vacuna a base toxina clostridium difficile.
|
EP2802353A4
(de)
|
2012-01-12 |
2015-12-02 |
Variation Biotechnologies Inc |
Zusammensetzungen und verfahren zur behandlung von virusinfektionen
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
US20150079077A1
(en)
|
2012-01-27 |
2015-03-19 |
Variation Biotechnologies, Inc. |
Methods and compositions for therapeutic agents
|
RS58868B1
(sr)
|
2012-02-07 |
2019-08-30 |
Infectious Disease Res Inst |
Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
|
CN104321335A
(zh)
|
2012-02-24 |
2015-01-28 |
诺华股份有限公司 |
菌毛蛋白质和组合物
|
US20130236484A1
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen Inc. |
Leishmaniasis antigen detection assays and vaccines
|
NZ630807A
(en)
|
2012-03-23 |
2016-04-29 |
Pitney Pharmaceuticals Pty Ltd |
Kinase inhibitors for the treatment of cancer
|
GB201205189D0
(en)
|
2012-03-23 |
2012-05-09 |
Glaxosmithkline Biolog Sa |
Novel medical use
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
BR112014024612A2
(pt)
|
2012-04-02 |
2021-06-08 |
Univ North Carolina Chapel Hill |
ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
CN108671228A
(zh)
|
2012-04-26 |
2018-10-19 |
诺华股份有限公司 |
抗原和抗原组合
|
EP2659906A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659907A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659908A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
SI2844282T1
(sl)
|
2012-05-04 |
2019-08-30 |
Pfizer Inc. |
S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
|
JP6619648B2
(ja)
|
2012-05-16 |
2019-12-11 |
イミューン デザイン コーポレイション |
Hsv−2のためのワクチン
|
SG10201608675YA
(en)
|
2012-05-22 |
2016-12-29 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
EP2666785A1
(de)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Auf Komplementfaktor C5a basierender Impfstoff
|
BR112014030436A2
(pt)
|
2012-06-05 |
2017-09-26 |
Univ Australian National |
método para induzir uma resposta imune antígeno-específico em um indivíduo, aumentar a avidez e o número de células imunitárias por um antígeno em um indivíduo, composição, método para a prevenção ou tratamento de uma infecção num indivíduo e de vacinação de um indivíduo contra uma infecção.
|
EP2859011B1
(de)
|
2012-06-06 |
2019-12-11 |
Bionor Immuno AS |
Peptide aus viralen proteinen zur verwendung als immunogene oder nachweisreagenzien
|
SG11201500439RA
(en)
|
2012-07-24 |
2015-02-27 |
Sanofi Pasteur |
Vaccine compositions for prevention against dengue virus infection
|
CN104812407B
(zh)
|
2012-07-24 |
2022-11-22 |
赛诺菲巴斯德有限公司 |
疫苗组合物
|
CN109266622B
(zh)
|
2012-08-01 |
2023-05-09 |
巴法里安诺迪克有限公司 |
重组改良型安卡拉痘苗病毒(mva)呼吸道合胞病毒(rsv)疫苗
|
EP4299138A2
(de)
|
2012-08-03 |
2024-01-03 |
Access to Advanced Health Institute |
Zusammensetzungen und verfahren zur behandlung einer aktiven mycobakterium-tuberkuloseinfektion
|
PL2880014T3
(pl)
|
2012-08-06 |
2017-10-31 |
Pitney Pharmaceuticals Pty Ltd |
Związki do leczenia chorób związanych ze szlakiem mTOR
|
JP2014040396A
(ja)
*
|
2012-08-23 |
2014-03-06 |
Chemo-Sero-Therapeutic Research Institute |
脂質異常症治療薬を含有するアジュバント組成物
|
EP2703483A1
(de)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 Peptidimpfstoff
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
CA2882382A1
(en)
|
2012-09-18 |
2014-03-27 |
Novartis Ag |
Outer membrane vesicles
|
ES2672996T3
(es)
|
2012-10-02 |
2018-06-19 |
Glaxosmithkline Biologicals Sa |
Conjugados de sacáridos no lineales
|
AR092896A1
(es)
|
2012-10-03 |
2015-05-06 |
Novartis Ag |
Composiciones inmunogenicas
|
EP2912186B1
(de)
|
2012-10-24 |
2021-01-06 |
Platelet Targeted Therapeutics LLC |
Gezielte thrombozytenbehandlung
|
WO2014083194A1
(en)
|
2012-11-30 |
2014-06-05 |
Sanofi Pasteur |
Methods for inducing antibodies
|
WO2014083060A2
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Pseudomonas antigens and antigen combinations
|
CA2893435A1
(en)
|
2012-12-05 |
2014-06-12 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
AU2013362878B2
(en)
|
2012-12-17 |
2017-03-30 |
Newsouth Innovations Pty Limited |
Treatment of diseases involving mucin
|
AU2013370932B2
(en)
|
2012-12-24 |
2019-02-21 |
Cell Ideas Pty Ltd |
Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
AU2014229561B2
(en)
|
2013-03-15 |
2018-06-07 |
Keith Alan Charlton |
Self-assembling synthetic proteins
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
WO2014172637A1
(en)
|
2013-04-18 |
2014-10-23 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
PL2994162T3
(pl)
*
|
2013-05-08 |
2021-10-18 |
Pharmgate Biologics Inc. |
Szczepionka przeciwko pcv2 i mykoplazmie
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
BR112015032388A8
(pt)
|
2013-06-26 |
2020-01-14 |
Univ North Carolina Chapel Hill |
glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
|
US10364277B2
(en)
|
2013-07-01 |
2019-07-30 |
Newsouth Innovations Pty Limited |
Diagnosis and treatment of autoimmune diseases
|
EP3039036B1
(de)
|
2013-08-28 |
2019-05-22 |
GlaxoSmithKline Biologicals S.A. |
Neuartige influenza-antigene und -antikörper
|
CN104436157A
(zh)
|
2013-09-23 |
2015-03-25 |
恩金生物有限公司 |
流感疫苗和治疗
|
EP3063171B1
(de)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albuminvarianten und verwendungen davon
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
US20160287696A1
(en)
|
2013-11-20 |
2016-10-06 |
La Jolla Institute For Allergy And Immunology |
Pan pollen immunogens and methods and uses for immune response modulation
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
KR20240023713A
(ko)
|
2013-12-31 |
2024-02-22 |
액세스 투 어드밴스드 헬스 인스티튜트 |
단일 바이알 백신 제형
|
EP3092302A4
(de)
|
2014-01-06 |
2017-06-07 |
The United States of America, as Represented by the Secretary of Agriculture |
Abgeschwächte salmonella enterica
|
RU2771293C2
(ru)
|
2014-01-21 |
2022-04-29 |
Пфайзер Инк. |
Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
|
MA39228A1
(fr)
|
2014-01-21 |
2017-06-30 |
Immune Design Corp |
Compositions à utiliser pour le traitement d'états allergiques
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US10279019B2
(en)
|
2014-02-11 |
2019-05-07 |
Stc.Unm |
PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
US10426828B2
(en)
|
2014-04-03 |
2019-10-01 |
Biondvax Pharmaceuticals Ltd. |
Compositions of multimeric-multiepitope influenza polypeptides and their production
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
EP3169699A4
(de)
|
2014-07-18 |
2018-06-20 |
The University of Washington |
Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
|
WO2016012385A1
(en)
|
2014-07-21 |
2016-01-28 |
Sanofi Pasteur |
Vaccine composition comprising ipv and cyclodextrins
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
EP4112076A1
(de)
|
2014-10-10 |
2023-01-04 |
The Regents of The University of Michigan |
Nanoemulsionszusammensetzungen zur prävention, unterdrückung oder eliminierung von allergischen und entzündlichen erkrankungen
|
BR112017008952A2
(pt)
|
2014-11-02 |
2018-01-16 |
Univ North Carolina Chapel Hill |
métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
EP3229833A1
(de)
|
2014-12-10 |
2017-10-18 |
GlaxoSmithKline Biologicals SA |
Behandlungsverfahren
|
WO2016109880A1
(en)
|
2015-01-06 |
2016-07-14 |
Immunovaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
AU2016207820B2
(en)
|
2015-01-15 |
2020-12-17 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
MX2017010698A
(es)
|
2015-02-20 |
2018-04-30 |
Univ Texas |
Metodos y composiciones para chlamydia atenuada como vacuna y vector.
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
EP3270897A4
(de)
|
2015-03-20 |
2018-12-05 |
The Regents Of The University Of Michigan |
Immunogene zusammensetzungen zur verwendung als impfstoff gegen bordetella
|
KR20170129786A
(ko)
|
2015-03-26 |
2017-11-27 |
지피앤 백신즈 피티와이 엘티디 |
연쇄상구균 백신
|
BR112017025316A2
(pt)
|
2015-05-26 |
2018-07-31 |
Ohio State Innovation Foundation |
estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
AU2016281904B2
(en)
|
2015-06-26 |
2022-08-11 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
RU2018104362A
(ru)
|
2015-07-07 |
2019-08-08 |
Аффирис Аг |
ВАКЦИНЫ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ IgE
|
TWI684460B
(zh)
|
2015-07-21 |
2020-02-11 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
WO2017040790A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
ES2607715B1
(es)
|
2015-10-01 |
2018-01-17 |
Solutex Na, Lcc |
Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
EP3377098A1
(de)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
JP7089470B2
(ja)
|
2015-12-02 |
2022-06-22 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
WO2017109698A1
(en)
|
2015-12-22 |
2017-06-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic formulation
|
KR20200109395A
(ko)
|
2016-01-19 |
2020-09-22 |
화이자 인코포레이티드 |
암 백신
|
GB201603625D0
(en)
|
2016-03-02 |
2016-04-13 |
Glaxosmithkline Biolog Sa |
Novel influenza antigens
|
CA3017356A1
(en)
|
2016-03-10 |
2017-09-14 |
Aperisys, Inc. |
Antigen-binding fusion proteins with modified hsp70 domains
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
GEP20217232B
(en)
|
2016-03-14 |
2021-03-25 |
I Oslo Universitetet |
Engineered immunoglobulins with altered fcrn binding
|
WO2017167768A1
(en)
|
2016-03-28 |
2017-10-05 |
Glaxosmithkline Biologicals S.A. |
Novel vaccine composition
|
DK3458475T3
(da)
|
2016-05-16 |
2022-09-12 |
Access To Advanced Health Inst |
Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
WO2017205225A2
(en)
|
2016-05-21 |
2017-11-30 |
Infectious Disease Research Institute |
Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
|
MX2018014387A
(es)
|
2016-05-27 |
2019-03-14 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
IL298227A
(en)
|
2016-06-01 |
2023-01-01 |
Access To Advanced Health Inst |
Nanoalum particles containing a fixing factor
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US11780924B2
(en)
|
2016-06-21 |
2023-10-10 |
University Of Oslo |
HLA binding vaccine moieties and uses thereof
|
BR112019003462A2
(pt)
|
2016-08-23 |
2019-06-25 |
Glaxosmithkline Biologicals Sa |
proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
BR112019004913B1
(pt)
|
2016-09-16 |
2022-07-12 |
Infectious Disease Research Institute |
Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
AU2017343621B2
(en)
|
2016-10-11 |
2021-12-02 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
KR20190103226A
(ko)
|
2017-01-13 |
2019-09-04 |
아게누스 인코포레이티드 |
Ny-eso-1에 결합하는 t 세포 수용체 및 이의 사용 방법
|
BR112019014833A2
(pt)
|
2017-01-20 |
2020-04-14 |
Pfizer |
composições imunogênicas para uso em vacinas pneumococais
|
KR20190135017A
(ko)
|
2017-03-30 |
2019-12-05 |
더 유니버서티 어브 퀸슬랜드 |
키메라 분자 및 그의 용도
|
BR112019020209A2
(pt)
|
2017-03-31 |
2020-06-02 |
Glaxosmithkline Intellectual Property Development Limited |
Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
HRP20230941T1
(hr)
|
2017-05-01 |
2023-11-24 |
Agenus Inc. |
Anti-tigit antitijela i postupci njihove primjene
|
SG11201911930SA
(en)
|
2017-06-11 |
2020-01-30 |
Molecular Express Inc |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR20200028395A
(ko)
|
2017-06-15 |
2020-03-16 |
인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
RU2020106669A
(ru)
|
2017-07-18 |
2021-08-18 |
Ин3Байо Лтд. |
Синтетические белки и пути их терапевтического применения
|
JP2020530478A
(ja)
|
2017-08-14 |
2020-10-22 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫応答を強化する方法
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
WO2019048936A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
WO2019051149A1
(en)
|
2017-09-08 |
2019-03-14 |
Infectious Disease Research Institute |
LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
|
WO2019079594A1
(en)
|
2017-10-18 |
2019-04-25 |
The University Of North Carolina At Chapel Hill |
METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
|
JP7295124B2
(ja)
|
2017-11-03 |
2023-06-20 |
タケダ ワクチン,インコーポレイテッド |
ジカワクチン及び免疫原性組成物、ならびにその使用方法
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
US11702674B2
(en)
|
2018-06-12 |
2023-07-18 |
Glaxosmithkline Biologicals Sa |
Simian adenovirus vectors comprising the ChAd-157 fiber protein
|
BR112021000965A2
(pt)
|
2018-08-07 |
2021-04-27 |
Glaxosmithkline Biologicals S.A. |
processos e vacinas
|
US20210220462A1
(en)
|
2018-08-23 |
2021-07-22 |
Glaxosmithkline Biologicals Sa |
Immunogenic proteins and compositions
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP3843782A1
(de)
|
2018-08-29 |
2021-07-07 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Ebolaimpfstoffzusammensetzungen und verfahren zu ihrer verwendung
|
EP3851120A4
(de)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
Immunogen für influenza-impfstoff mit breitem spektrum und anwendung davon
|
US20220000779A1
(en)
|
2018-12-06 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
EP3893926A1
(de)
|
2018-12-12 |
2021-10-20 |
Pfizer Inc. |
Immunogene multiple hetero-antigen-polysaccharid-protein-konjugate und deren verwendung
|
US20220054632A1
(en)
|
2018-12-12 |
2022-02-24 |
Glaxosmithkline Biologicals Sa |
Modified carrier proteins for o-linked glycosylation
|
US20220184158A1
(en)
|
2018-12-21 |
2022-06-16 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
CN113573730A
(zh)
|
2019-03-05 |
2021-10-29 |
葛兰素史密斯克莱生物公司 |
乙型肝炎免疫方案和组合物
|
WO2020208502A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
US20220221455A1
(en)
|
2019-04-18 |
2022-07-14 |
Glaxosmithkline Biologicals Sa |
Antigen binding proteins and assays
|
WO2020243115A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
CN114269792A
(zh)
|
2019-06-25 |
2022-04-01 |
因斯瑞拜奥有限公司 |
稳定的嵌合合成蛋白及其治疗用途
|
CN114206909A
(zh)
|
2019-07-21 |
2022-03-18 |
葛兰素史克生物有限公司 |
治疗性病毒疫苗
|
EP3770269A1
(de)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantifizierung von biokonjugatglykosylierung
|
CN114667158A
(zh)
|
2019-08-05 |
2022-06-24 |
葛兰素史克生物有限公司 |
免疫原性组合物
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
EP3799884A1
(de)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzungen
|
EP3808765A1
(de)
|
2019-10-14 |
2021-04-21 |
ETH Zurich |
Zelllinie für tcr-entdeckung und -engineering und verwendungsverfahren dafür
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
WO2021097347A1
(en)
|
2019-11-15 |
2021-05-20 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
EP4093873A1
(de)
|
2020-01-24 |
2022-11-30 |
Aim Immunotech Inc. |
Verfahren, zusammensetzungen und impfstoffe zur behandlung einer virusinfektion
|
WO2021160887A1
(en)
|
2020-02-14 |
2021-08-19 |
Immunor As |
Corona virus vaccine
|
WO2021165847A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
BR112022014555A2
(pt)
|
2020-02-23 |
2022-09-20 |
Pfizer |
Composições de escherichia coli e métodos das mesmas.
|
FI20215508A1
(en)
|
2020-04-09 |
2021-10-10 |
Niemelae Erik Johan |
Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
|
EP4161570A1
(de)
|
2020-06-05 |
2023-04-12 |
GlaxoSmithKline Biologicals S.A. |
Modifizierte spike-proteine des betacoronavirus
|
EP4171629A1
(de)
|
2020-06-29 |
2023-05-03 |
GlaxoSmithKline Biologicals S.A. |
Adjuvans
|
CN116507345A
(zh)
|
2020-08-17 |
2023-07-28 |
巴塞尔大学 |
用于癌症疗法的lfa-1信号传导介体
|
JP2023538665A
(ja)
|
2020-08-24 |
2023-09-08 |
サノフィ パスツール インコーポレイテッド |
トコフェロール含有スクアレンエマルションアジュバントを有するcovid-19ワクチン
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
WO2022083760A1
(zh)
|
2020-10-23 |
2022-04-28 |
江苏省疾病预防控制中心(江苏省公共卫生研究院) |
融合蛋白及其应用
|
IL302362A
(en)
|
2020-10-27 |
2023-06-01 |
Pfizer |
ESCHERICHIA COLI preparations and their methods
|
IL302413A
(en)
|
2020-11-04 |
2023-06-01 |
Pfizer |
Immunogenic preparations for use in pneumococcal vaccines
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
EP4277654A1
(de)
|
2021-01-18 |
2023-11-22 |
Conserv Bioscience Limited |
Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon
|
EP4032547A1
(de)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce abgeleitete fragemente zur hsv therapie
|
WO2022178196A1
(en)
|
2021-02-19 |
2022-08-25 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
WO2022175423A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition, use and methods
|
WO2022200582A1
(en)
|
2021-03-26 |
2022-09-29 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
US20220387613A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US20220387576A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
BR112023027401A2
(pt)
|
2021-06-28 |
2024-03-12 |
Glaxosmithkline Biologicals Sa |
Antígenos do vírus influenza
|
WO2023020994A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020992A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023020993A1
(en)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Novel methods
|
WO2023061993A1
(en)
|
2021-10-13 |
2023-04-20 |
Glaxosmithkline Biologicals Sa |
Polypeptides
|
WO2023092090A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|